<DOC>
	<DOCNO>NCT03106259</DOCNO>
	<brief_summary>Observational Study evaluate safety FURESTEM-RA lnj . moderate severe rheumatoid arthritis patient participate phase 1 clinical trial FURESTEM-RA lnj .</brief_summary>
	<brief_title>Observational Study Assess Safety FURESTEM-RA Lnj . In Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description>This observational study , single center , open label , study safety FURESTEM-RA Inj . subject moderate severe rheumatoid arthritis . Subjects participate observational study originally participate study FURESTEM-RA Inj . [ NCT02221258 ]</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects participate observational study originally participate study FURESTEMRA Inj . [ NCT02221258 ] Subject understand voluntarily sign informed consent form In case followup possible end clinical trial Phase 1 end study period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>FURESTEM-RA</keyword>
</DOC>